Finally, our data suggest that inactivation of aberrant TLR4 function offer a novel therapeutic strategy to prevent and/or treat obesity-induced cardiac insulin resistance and its associated cardiovascular co-morbidities. Here, TLR4 is linked to obesity due to melanocortin 4 receptor deficiency.